Last reviewed · How we verify
NCT07535749
The Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children
Phase 3 trial testing MiSight Contact Lenses (CooperVision) in Myopia Progression in 66 participants. Currently enrolling.
30 November 2026
Quick facts
| Lead sponsor | Aston University |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 66 |
| Start date | 21 March 2026 |
| Primary completion | 30 November 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across New Zealand |
Drugs / interventions tested
- MiSight Contact Lenses (CooperVision)
- Albiliti 1-Day (Johnson and Johnson, VisionCare)
Conditions studied
- Myopia Progression — all drugs for Myopia Progression →
Sponsor
Aston University
Who can join
Adults 7 to 11, any sex, with Myopia Progression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will employ a randomized, controlled, investigator-masked paired-eye comparison design to evaluate the effects of two myopia-control contact lenses-MiSight 1 Day and Abiliti 1-Day-in New Zealand Chinese children. The study duration will be 6 months, with assessments conducted at baseline, 2 weeks, 3 months, and 6 months. The clinical research will be conducted at the Auckland Myopia Clinic (New Zealand) and will follow a standard clinical routine for children with early myopia, the only difference being the randomizing of the MiSight and Abiliti contact lenses between the two eyes of the participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07535749
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myopia Progression
Currently open trials in the same condition.
- NCT07229365 — Children's Viewing Behavior · NA · recruiting
- NCT06878118 — The A.R.R.E.S.T.® Contact Lens Study · NA · recruiting
- NCT06631339 — Optimizing Light Exposure for Myopia Prevention and Control (LightSPAN) · NA · recruiting
- NCT06708156 — The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatri · Phase 3 · recruiting
- NCT06498947 — Factors Influencing Physiological Hyperopia in Children · recruiting
Other Aston University trials
Trials by the same sponsor.
- NCT06745375 — Assessment of the Relationship of Soft Contact Lens Fit and Power (Fit & Lens pOwer Soft lenSes) · NA · enrolling by invitation
- NCT07378397 — OPM MEG in Pre-surgical Mapping for Patients With Epilepsy · enrolling by invitation
- NCT06615453 — Impact of Tixel Treatment on Symptoms and Signs in Patients With Dry Eye Disease · NA · recruiting
- NCT06163989 — Protecting the Eyes of Gamers With Lubricating Eyedrops · NA · recruiting
- NCT06371300 — Photobiomodulation With REd vs BluE Light (REBEL) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07535749 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aston University
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07535749.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing